Breathe Well Live Well
Condition: Asthma
Interventions: Drug: BHT 0.1%; Drug: BHT 0.5%; Drug: Placebo for RMT-B; Drug: Placebo for HFA-MDI
Sponsor: Boehringer Ingelheim
Completed – verified August 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
SeniorJournal.com |
FDA approves Striverdi Respimat for COPD, includes asthma warning
Healio “The safety and effectiveness of Striverdi Respimat in people with asthma has not been established, and it is not approved to treat asthma,” the release said. “Striverdi Respimat should not be used as a rescue therapy to treat sudden breathing problems … FDA Clears Olodaterol (Striverdi Respimat) for COPD Once-Daily Inhaler Approved for COPD FDA approves Boehringer's once-a-day inhaler drug |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Berodual® Respimat®, low dose; Drug: Berodual® Respimat®, high dose; Drug: Berodual® MDI
Sponsor: Boehringer Ingelheim
Completed – verified July 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Respimat® Budesonide low dose; Drug: Respimat® Budesonide high dose; Drug: Turbohaler® Budesonide; Drug: Placebo
Sponsor: Boehringer Ingelheim
Completed – verified July 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Phase III studies show tiotropium delivered via Respimat inhaler proves …
News-Medical.net Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at … |
View full post on asthma – Google News
|
ASTHMA: New Phase III data show tiotropium * Respimat ® effective across …
Business Wire (press release) Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at … |
View full post on asthma – Google News
|
New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA …
News-Medical.net These were the main findings from a new subset of data from the Phase III UniTinA-asthma® programme presented for the first time today at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic … |
View full post on asthma – Google News
|
Phase III results: tiotropium* Respimat® is effective in symptomatic asthma …
Business Wire (press release) SAN ANTONIO, Texas–(BUSINESS WIRE)–Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS†/LABA‡, irrespective … Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Olodaterol (BI 1744); Drug: Olodaterol (BI 1744); Drug: Olodaterol (BI 1744) low; Drug: Olodaterol (BI 1744) high; Drug: Formoterol 12 mcg; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days